COST-UTILITY ANALYSIS OF SOFOSBUVIR FOR TREATMENT OF GENOTYPE2 CHRONIC HEPATITIS C IN JAPAN

被引：1
|
作者：
Igarashi, A. [1 ]
Tang, W. [1 ]
Cure, S. [2 ]
Guerra, I [2 ]
Lopresti, M. [3 ]
Tsutani, K. [1 ]
机构：
[1] Univ Tokyo, Grad Sch Pharmaceut Sci, Tokyo, Japan
[2] OptumInsight, Uxbridge, Middx, England
[3] Junicon Japan Inc, Minato Ku, Tokyo, Japan
来源：
VALUE IN HEALTH | 2014年 / 17卷 / 07期
关键词：
D O I：
10.1016/j.jval.2014.08.827
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PGI30
引用
收藏
页码：A368 / A368
页数：1
相关论文
共 50 条
  • [1] Cost-utility analysis of sofosbuvir for the treatment of genotype 2 chronic hepatitis C in Japan
    Igarashi, Ataru
    Tang, Wentao
    Cure, Sandrine
    Guerra, Ines
    Marie, Lucile
    Lopresti, Michael
    Tsutani, Kiichiro
    CURRENT MEDICAL RESEARCH AND OPINION, 2017, 33 (01) : 1 - 10
  • [2] Cost-utility analysis of ledipasvir/sofosbuvir for the treatment of genotype 1 chronic hepatitis C in Japan
    Igarashi, Ataru
    Tang, Wentao
    Guerra, Ines
    Marie, Lucile
    Cure, Sandrine
    Lopresti, Michael
    CURRENT MEDICAL RESEARCH AND OPINION, 2017, 33 (01) : 11 - 21
  • [3] Cost-Utility Analysis of Direct-Acting Antivirals for Treatment of Chronic Hepatitis C Genotype 1 and 6 in Vietnam
    Ong The Due
    Thakkinstian, Ammarin
    Thavorncharoensap, Montarat
    Sobhonslidsuk, Abhasnee
    Wu, Olivia
    Nguyen Khanh Phuong
    Chaikledkaew, Usa
    VALUE IN HEALTH, 2020, 23 (09) : 1180 - 1190
  • [4] Cost-Utility of Elbasvir/Grazoprevir in Patients with Chronic Hepatitis C Genotype 1 Infection
    Corman, Shelby
    Elbasha, Elamin H.
    Michalopoulos, Steven N.
    Nwankwo, Chizoba
    VALUE IN HEALTH, 2017, 20 (08) : 1110 - 1120
  • [5] Cost-utility of chronic hepatitis "C" treatment with thymosin alpha 1 in Mexico
    Nevárez-Sida, A
    Garcia-Contreras, F
    Constantino-Casas, P
    Castro-Rios, A
    Mould, J
    Garduño-Espinosa, J
    VALUE IN HEALTH, 2005, 8 (03) : 309 - 309
  • [6] COST-EFFECTIVENESS ANALYSIS OF SOFOSBUVIR FOR GENOTYPE 2 HEPATITIS C IN GREECE
    Athanasakis, K.
    Boubouchairopoulou, N.
    Kyriopoulos, I
    Tsoulas, C.
    Tzanakis, B.
    Kyriopoulos, J.
    VALUE IN HEALTH, 2016, 19 (07) : A415 - A415
  • [7] Cost-utility analysis of four WHO-recommended sofosbuvir-based regimens for the treatment of chronic hepatitis C in sub-Saharan Africa
    Sylvie Boyer
    Maël Baudoin
    Marie Libérée Nishimwe
    Melina Santos
    Maud Lemoine
    Gwenaëlle Maradan
    Babacar Sylla
    Charles Kouanfack
    Patrizia Carrieri
    Abbas Mourad
    Nicolas Rouveau
    Raoul Moh
    Moussa Seydi
    Alain Attia
    Maame Esi Woode
    Karine Lacombe
    BMC Health Services Research, 22
  • [8] Cost-utility analysis of four WHO-recommended sofosbuvir-based regimens for the treatment of chronic hepatitis C in sub-Saharan Africa
    Boyer, Sylvie
    Baudoin, Mael
    Nishimwe, Marie Liberee
    Santos, Melina
    Lemoine, Maud
    Maradan, Gwenaelle
    Sylla, Babacar
    Kouanfack, Charles
    Carrieri, Patrizia
    Mourad, Abbas
    Rouveau, Nicolas
    Moh, Raoul
    Seydi, Moussa
    Attia, Alain
    Woode, Maame Esi
    Lacombe, Karine
    BMC HEALTH SERVICES RESEARCH, 2022, 22 (01)
  • [9] Cost-Utility Analysis of Tenofovir Disoproxil Fumarate in the Treatment of Chronic Hepatitis B
    Dakin, Helen
    Bentley, Anthony
    Dusheiko, Geoff
    VALUE IN HEALTH, 2010, 13 (08) : 922 - 933
  • [10] Cost-utility of sofosbuvir/velpatasvir versus other direct-acting antivirals for chronic hepatitis C genotype 1b infection in China
    Yun, Haoya
    Zhao, Guoqiang
    Sun, Xiaojie
    Shi, Lizheng
    BMJ OPEN, 2020, 10 (08):
12345